ARTICLE | Clinical News
GTI-2040: Phase I started
June 25, 2007 7:00 AM UTC
LOR began an open-label, U.S. Phase I trial in patients to evaluate intravenous GTI-2040 in patients with relapsed, refractory or high-risk acute myelogenous leukemia (AML), acute lymphoblastic leukem...